KOSDAQBiotech & Pharma047920

HLB Pharmaceutical

₩6,630▼ 2.93%2026-11-18 close
Market Cap
₩288.8B
Turnover
₩1.1B
Volume
170K
Shares out.
43.6M
PER
70.9×
PBR
1.2×
EPS
₩103
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Growth Is Clear; Profitability Still Unproven

HLB Pharmaceutical lifted 2025 sales to KRW 205.6 billion, but its 0.5% operating margin means earnings strength is still being proven.

  1. 1

    Revenue grew for three consecutive years from 2023 to 2025, and 2025 sales rose 50.0% to KRW 205.6 billion.

  2. 2

    Operating profit fell 27.8% to KRW 1.06 billion in 2025, leaving a 0.5% operating margin, so sales growth has not yet lifted margins.

  3. 3

    According to company announcements, consolidated H1 2026 sales reached KRW 127.9 billion, up 57% year on year, and Q3 2026 returned to operating profit of KRW 847 million after a Q2 loss.

  4. 4

    A KRW 55 billion plant in Hyangnam broke ground on November 12, 2026. Its target capacity of about 700 million tablets a year is roughly three times the Namyangju plant, and it aims to bring outsourced production in-house.

  5. 5

    Anticancer drugs including rivoceranib are in the U.S. FDA review process, and Chairman Jin Yang-gon said at the November 12, 2026 groundbreaking that he is confident of a second anticancer drug approval.

02

Business structure

HLB Pharmaceutical was founded in 1998 under a previous name, listed on KOSDAQ in 2015, and adopted its current name after joining HLB Group in 2020. Prescription drugs (ETC) are the core of its sales.

According to company figures, ETC sales reached KRW 69 billion in H1 2026, up 12% year on year, with several major products growing in double digits. The company attributed H1 2026 sales growth to its pharmaceutical business together with the consolidation of subsidiary results.

It also plans to widen its mix into consumer healthcare and medical devices on top of the existing drug business. The pipeline centers on anticancer drugs: rivoceranib combined with camrelizumab for liver cancer and lirafugratinib for cholangiocarcinoma have both been filed with the U.S. FDA.

A long-acting injectable is being developed on the company's in-house SMEB drug delivery platform. R&D spending in H1 2026 was KRW 3.57 billion, up 35.3%. On production, the company is moving outsourced manufacturing in-house.

It is grouped with listed Korean pharmaceutical companies that focus on prescription drugs, and generic drug price cuts are cited as a shared industry pressure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩60.6B₩34,119,4300.1%
2025Q4₩63.4B₩800M1.3%
2026Q1₩65.7B₩1B1.6%
2026Q2₩62.3B-₩30,961,995−0.0%
2026Q3₩62.5B₩800M1.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩107.5B-₩6.4B-₩11.8B−6.0%−13.7%65.5%
2023₩136B-₩19.5B-₩19.4B−14.4%−22.0%60.3%
2024₩137.1B₩1.5B₩2B1.1%1.7%35.7%
2025₩205.6B₩1.1B₩4.6B0.5%3.7%36.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, sales rose from KRW 107.5 billion in 2022 to KRW 205.6 billion in 2025. Sales grew 26.5% to KRW 136 billion in 2023 and 0.8% to KRW 137.1 billion in 2024, and then 50.0% in 2025, the largest rise in the period.

Operating losses of KRW 6.44 billion in 2022 and KRW 19.5 billion in 2023 turned into operating profit of KRW 1.47 billion in 2024. Operating profit then fell 27.8% to KRW 1.06 billion in 2025, and the operating margin slipped from 1.1% to 0.5%.

Profit attributable to controlling shareholders moved from a loss of KRW 19.4 billion in 2023 to a profit of KRW 2.02 billion in 2024, and rose 126.3% to KRW 4.57 billion in 2025. Because that profit rose while operating profit fell, items outside operations appear to have contributed meaningfully in 2025.

Net profit including non-controlling interests was also KRW 4.57 billion in 2025. Operating cash flow was -KRW 2.76 billion in 2022 and -KRW 18.3 billion in 2023, turned to KRW 6.84 billion in 2024, and fell to KRW 569 million in 2025.

The debt ratio (total liabilities divided by total equity) fell from 65.5% in 2022 to 36.4% in 2025, with equity of KRW 125.1 billion and total liabilities of KRW 45.5 billion at end-2025. Quarterly sales moved from KRW 60.6 billion in Q3 2025 to KRW 62.5 billion in Q3 2026, up 3.1% year on year.

Operating profit rose from KRW 34.12 million in Q3 2025 to KRW 835 million in Q4 2025 and KRW 1.03 billion in Q1 2026, then turned into an operating loss of KRW 30.96 million in Q2 2026. Q3 2026 returned to operating profit of KRW 847 million.

Profit attributable to controlling shareholders over the last four quarters totaled KRW 3.37 billion. In an announcement dated August 14, 2026, the company put consolidated H1 2026 sales at KRW 127.9 billion, up 57%, and operating profit at about KRW 1 billion, up 414%.

05

Industry analysis

Korea's pharmaceutical sector faces continuing generic drug price cut pressure, which is pushing companies to lower production costs. HLB Pharmaceutical plans to produce its own products at the Hyangnam plant instead of relying on outside manufacturers, aiming to cut costs and raise quality.

This approach reflects the view that cost control determines profitability in a business where repeated price cuts occur. The company also plans to use spare capacity at the new plant to launch new products and expand contract manufacturing (CMO), including securing outside customers' volume to raise plant utilization.

Its prescription-focused sales mix makes it comparable with listed peers that pair anticancer drug development with prescription sales, and Hanmi Pharm, Yuhan, SAM Chun Dang Pharm and Celltrion are often mentioned in the same sector.

A direct comparison with these companies would need to separate sales scale, pipeline stage and overseas approval progress. On the pipeline side, the U.S. approval process for its anticancer drugs is the key variable, and the sector comparison may shift depending on how that process goes.

At group level, the Hyangnam plant has been proposed as a domestic production base for HLB Group's new drugs, including rivoceranib.

06

Outlook

The company has set a medium- to long-term target of KRW 1 trillion in sales by 2036 and entry into the top 10 Korean pharmaceutical companies. It plans to focus on improving pharmaceutical profitability in 2027 to 2028, then expand improved new drug development and hospital sales in 2029 to 2031.

Afterward, it intends to broaden its product lineup into oncology, urology and rare diseases, while pursuing large product licensing and M&A.

The Hyangnam plant targets completion of the building's occupancy approval by the end of 2027, and after GMP certification steps, manufacturing functions will move from the Namyangju plant in phases starting in 2029.

Reports differ on timing, however: one outlet cited completion in August 2027 and mass production in October 2028, while another cited a January 31, 2028 completion target.

On funding, a rights offering with a general public offering of unsubscribed shares, sized at KRW 60.9 billion, was under way when the company announced it in August 2026.

On the pipeline side, a related article headline pointed to an expected FDA resubmission for the liver cancer drug, and Chairman Jin said he is confident of a second anticancer drug approval.

At group level, a production campus linking the Hyangnam site with adjacent land and domestic production of a long-acting injectable were also mentioned. The next checkpoints are therefore whether the plant schedule holds and how the FDA review progresses.

07

Valuation

PER
70.9×
PBR
1.2×
ROE
2.1%
EPS
₩103
BPS
₩6,099
Dividend per share
₩0

The current share price sits at a high earnings multiple compared with the KRW 3.37 billion of controlling-shareholder profit over the last four quarters, reflecting a thin profit base. The price-to-book ratio is slightly above 1x, which means the stock carries a premium over net asset value.

The dividend yield is effectively near zero, so shareholder returns through dividends are low. Because the profit base is small, the multiple moves sharply with quarterly results. Profit attributable to controlling shareholders turned positive in 2024 and rose in 2025, which points to earnings recovery.

However, quarterly losses appeared in Q3 2025 and Q2 2026, so quarterly multiples vary widely over time. The rights offering of KRW 60.9 billion that was under way when announced in August 2026 would increase the share count and should be considered when comparing per-share measures.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Sales Growth and a Return to Quarterly Profit

Sales rose for three consecutive years from 2023 to 2025, including a 50.0% increase in 2025. The company said H1 2026 sales of KRW 127.9 billion were its best first-half result on record.

Three of the last four quarters showed profit attributable to controlling shareholders, and Q3 2026 operating profit of KRW 847 million returned the company to profit after the Q2 loss. Supporters cite this trend as the main strength.

Room for Cost Gains from In-House Production

The Hyangnam plant is designed to lift annual capacity to about 700 million tablets, roughly three times the Namyangju plant. The company plans to move outsourced volume in-house to reduce manufacturing costs, and to use spare capacity for contract manufacturing. The company's argument is that a better cost structure could lift the operating margin above current levels.

Anticancer Approval Progress and Group Production Links

Rivoceranib in combination therapy and lirafugratinib have been filed for U.S. FDA marketing approval. Chairman Jin Yang-gon said at the November 12, 2026 groundbreaking that he is confident of a second anticancer drug approval.

Because the Hyangnam plant is also planned as a production base for group drugs, supporters point to closer production links once approvals arrive.

09

Bear factors

Thin Operating Margin and a Small Profit Base

The operating margin was 0.5% in 2025, and operating profit fell 27.8%. Profit attributable to controlling shareholders over the last four quarters totaled KRW 3.37 billion, which is small relative to sales. A Q2 2026 operating loss of KRW 30.96 million shows quarterly volatility. Whether the earnings base has stabilized remains a weakness that more quarterly results will need to confirm.

Uncertainty Over the Liver Cancer Drug Approval

Reports noted that the liver cancer candidate rivoceranib in combination therapy had already suffered two setbacks. Related coverage points to an expected FDA resubmission, so the timing and result of approval are not settled.

If approval is delayed, the contribution from new drug sales could fall behind the medium- to long-term targets.

Investment Burden and Dilution Risk

The Hyangnam plant requires KRW 55 billion, and the rights offering announced in August 2026 was sized at KRW 60.9 billion. Cost benefits from in-house production are expected to appear in phases from 2029, so near-term profit gains look limited. Continued generic price cut pressure is another variable that could weigh on profitability.

10

Risk factors

Approval and Regulatory Risk

FDA review outcomes are beyond the company's control. The value of the pipeline depends on the timing of the liver cancer drug resubmission and the review of the cholangiocarcinoma candidate. A delay or rejection would lengthen the route to the medium- to long-term sales target.

Funding and Dilution Risk

Given KRW 55 billion for the plant and a KRW 60.9 billion rights offering, financial strain and a larger share count could arrive together. The debt ratio stood at 36.4% at end-2025, but cash flow during the heavy investment period will be the key test. Operating cash flow fell to KRW 569 million in 2025 from KRW 6.84 billion in 2024.

Execution and Consolidated Results Risk

Reports differ on the plant's completion date, with one citing August 2027 completion and October 2028 mass production, and another citing a January 31, 2028 completion target. Because consolidation of subsidiary results lifts consolidated sales, changes in that effect could alter reported growth rates.

11

What to watch next

  1. December 2026 onward (timing not fixed)

    Whether and when the liver cancer drug is resubmitted to the FDA. Related headlines anticipate a resubmission, but the timing is not confirmed, and any approval outcome depends on the review period that follows.

  2. By end of March 2027

    Filing of the 2026 annual report, which will confirm Q4 2026 results in a regular report. It is the point at which the full-year 2026 operating margin and profit trend can be checked.

  3. Mid-May 2027

    The Q1 2027 quarterly report. Because the company says it will focus on improving pharmaceutical profitability in 2027 to 2028, this is where operating margin and profit attributable to controlling shareholders can be tracked.

  4. End of 2027 (company target)

    Building occupancy approval for the Hyangnam plant. Reports give different completion dates, so schedule changes need to be watched; GMP certification would follow, and manufacturing would shift from the Namyangju plant from 2029.

12

Overall view

HLB Pharmaceutical grew sales from KRW 107.5 billion in 2022 to KRW 205.6 billion in 2025, and quarterly sales stayed in the KRW 60 billion range through Q3 2026.

On earnings, profit attributable to controlling shareholders rose to KRW 4.57 billion in 2025 after turning positive in 2024, but the 0.5% operating margin shows the earnings base is still thin. The Q2 2026 operating loss and the Q3 2026 return to profit show that quarterly results remain volatile.

The Hyangnam plant and the shift to in-house production leave room for gains in cost-related business indicators, but the effects are expected to appear in phases from 2029.

Whether the anticancer drugs win FDA approval is a separate variable that will shape the medium- to long-term growth path, and the resubmission timing of the liver cancer drug and the review of the cholangiocarcinoma candidate are the main checkpoints.

Strengths include sales growth, in-house production and the anticancer pipeline, while weaknesses include the thin operating margin, financial strain from the plant and rights offering, and approval uncertainty.

Weighing both sides equally, the current stage is one where growth direction and the test of profitability are running side by side.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. view.asiae.co.kr
  2. en.sedaily.com
  3. dailian.co.kr
  4. insight.goover.ai
  5. news.bizwatch.co.kr
  6. hitnews.co.kr
  7. asiatoday.co.kr
  8. news.bizwatch.co.kr
  9. wowtv.co.kr
  10. mydaily.co.kr
  11. mediafine.co.kr
  12. pinpointnews.co.kr
  13. news.mtn.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis